Literature DB >> 23678172

The B-cell-specific transcription factor and master regulator Pax5 promotes Epstein-Barr virus latency by negatively regulating the viral immediate early protein BZLF1.

Ryan M Raver1, Amanda R Panfil, Stacy R Hagemeier, Shannon C Kenney.   

Abstract

The latent-to-lytic switch of Epstein-Barr virus (EBV) is mediated by the immediate early protein BZLF1 (Z). However, the cellular factors regulating this process remain incompletely characterized. In this report, we show that the B-cell-specific transcription factor Pax5 helps to promote viral latency in B cells by blocking Z function. Although Z was previously shown to directly interact with Pax5 and inhibit its activity, the effect of Pax5 on Z function has not been investigated. Here, we demonstrate that Pax5 inhibits Z-mediated lytic viral gene expression and the release of infectious viral particles in latently infected epithelial cell lines. Conversely, we found that shRNA-mediated knockdown of endogenous Pax5 in a Burkitt lymphoma B-cell line leads to viral reactivation. Furthermore, we show that Pax5 reduces Z activation of early lytic viral promoters in reporter gene assays and inhibits Z binding to lytic viral promoters in vivo. We confirm that Pax5 and Z directly interact and show that this interaction requires the carboxy-terminal DNA-binding/dimerization domain of Z and the amino-terminal DNA-binding domain of Pax5. A Pax5 DNA-binding mutant (V26G/P80R) that interacts with Z retains the ability to inhibit Z function, whereas a Pax5 mutant (Δ106-110) that is deficient for interaction with Z does not inhibit Z-mediated lytic viral reactivation. Since the B-cell-specific transcription factor Oct-2 also directly interacts with Z and inhibits its function, these results suggest that EBV uses multiple redundant mechanisms to establish and maintain viral latency in B cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23678172      PMCID: PMC3700198          DOI: 10.1128/JVI.00546-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  73 in total

1.  DNA methylation inhibits transcription indirectly via a methyl-CpG binding protein.

Authors:  J Boyes; A Bird
Journal:  Cell       Date:  1991-03-22       Impact factor: 41.582

2.  The enhancer factor R of Epstein-Barr virus (EBV) is a sequence-specific DNA binding protein.

Authors:  H Gruffat; E Manet; A Rigolet; A Sergeant
Journal:  Nucleic Acids Res       Date:  1990-12-11       Impact factor: 16.971

3.  Analysis of the BZLF1 promoter of Epstein-Barr virus: identification of an anti-immunoglobulin response sequence.

Authors:  N Shimizu; K Takada
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

4.  Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-Barr virus early promoter, BMRF1.

Authors:  E B Quinlivan; E A Holley-Guthrie; M Norris; D Gutsch; S L Bachenheimer; S C Kenney
Journal:  Nucleic Acids Res       Date:  1993-07-11       Impact factor: 16.971

5.  An enhancer within the divergent promoter of Epstein-Barr virus responds synergistically to the R and Z transactivators.

Authors:  M A Cox; J Leahy; J M Hardwick
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

6.  Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1.

Authors:  E Flemington; S H Speck
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

7.  The zta transactivator involved in induction of lytic cycle gene expression in Epstein-Barr virus-infected lymphocytes binds to both AP-1 and ZRE sites in target promoter and enhancer regions.

Authors:  P M Lieberman; J M Hardwick; J Sample; G S Hayward; S D Hayward
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

8.  A human early B-cell factor-like protein participates in the regulation of the human CD19 promoter.

Authors:  R Gisler; P Akerblad; M Sigvardsson
Journal:  Mol Immunol       Date:  1999 Oct-Nov       Impact factor: 4.407

9.  Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas.

Authors:  R Glaser; H Y Zhang; K T Yao; H C Zhu; F X Wang; G Y Li; D S Wen; Y P Li
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

10.  Repression of genes by DNA methylation depends on CpG density and promoter strength: evidence for involvement of a methyl-CpG binding protein.

Authors:  J Boyes; A Bird
Journal:  EMBO J       Date:  1992-01       Impact factor: 11.598

View more
  15 in total

Review 1.  Emerging Proviral Roles of Caspases during Lytic Replication of Gammaherpesviruses.

Authors:  Tate Tabtieng; Marta M Gaglia
Journal:  J Virol       Date:  2018-09-12       Impact factor: 5.103

Review 2.  Regulation of the latent-lytic switch in Epstein-Barr virus.

Authors:  Shannon C Kenney; Janet E Mertz
Journal:  Semin Cancer Biol       Date:  2014-01-20       Impact factor: 15.707

3.  MYC Controls the Epstein-Barr Virus Lytic Switch.

Authors:  Rui Guo; Chang Jiang; Yuchen Zhang; Apurva Govande; Stephen J Trudeau; Fang Chen; Christopher J Fry; Rishi Puri; Emma Wolinsky; Molly Schineller; Thomas C Frost; Makda Gebre; Bo Zhao; Lisa Giulino-Roth; John G Doench; Mingxiang Teng; Benjamin E Gewurz
Journal:  Mol Cell       Date:  2020-04-20       Impact factor: 17.970

4.  Cellular differentiation regulator BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters.

Authors:  Jessica A Reusch; Dhananjay M Nawandar; Kenneth L Wright; Shannon C Kenney; Janet E Mertz
Journal:  J Virol       Date:  2014-11-19       Impact factor: 5.103

5.  Interaction of phospholipid scramblase 1 with the Epstein-Barr virus protein BZLF1 represses BZLF1-mediated lytic gene transcription.

Authors:  Shuichi Kusano; Masanori Ikeda
Journal:  J Biol Chem       Date:  2019-08-21       Impact factor: 5.157

6.  Epstein-Barr virus utilizes Ikaros in regulating its latent-lytic switch in B cells.

Authors:  Tawin Iempridee; Jessica A Reusch; Andrew Riching; Eric C Johannsen; Sinisa Dovat; Shannon C Kenney; Janet E Mertz
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

Review 7.  Keeping it quiet: chromatin control of gammaherpesvirus latency.

Authors:  Paul M Lieberman
Journal:  Nat Rev Microbiol       Date:  2013-11-06       Impact factor: 60.633

8.  Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression.

Authors:  Richard J Jones; Tawin Iempridee; Xiaobin Wang; Hans C Lee; Janet E Mertz; Shannon C Kenney; Heather C Lin; Veerabhadran Baladandayuthapani; Christopher W Dawson; Jatin J Shah; Donna M Weber; Robert Z Orlowski
Journal:  Clin Cancer Res       Date:  2016-06-13       Impact factor: 12.531

Review 9.  How do viruses trick B cells into becoming lymphomas?

Authors:  Ethel Cesarman
Journal:  Curr Opin Hematol       Date:  2014-07       Impact factor: 3.284

Review 10.  Epstein-Barr Virus: Diseases Linked to Infection and Transformation.

Authors:  Hem C Jha; Yonggang Pei; Erle S Robertson
Journal:  Front Microbiol       Date:  2016-10-25       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.